|Articles|August 14, 2018

Joseph Polli Named AAPS President-Elect

Pharmaceutical scientist association announces upcoming term’s board of directors.

Joseph W. Polli from GlaxoSmithKline has been elected to serve as president-elect of the American Association of Pharmaceutical Scientists (AAPS) and will begin a three-year term on the AAPS Board of Directors (as president-elect, president, and immediate past president) in November 2018 at the AAPS PharmSci 360 meeting in Washington, DC.

“My focus as president-elect will be to ensure that decisions from the AAPS Board of Directors drives member value, delivers the ongoing transformation of the association, and maintains the current fiscal stewardship, with a vision that AAPS will be prepared to serve and advance the capacity of the next generation of pharmaceutical scientists. It would be an honor to serve as the 2018–2019 president-elect,” Polli noted in his election bulletin.

AAPS also announced that Douglas H. Sweet, Virginia Commonwealth University, was elected as a member-at-large and Mark J. Rose, CHDI Management, Inc. was elected to serve as treasurer.

Other members on the 2019 AAPS Board of Directors are Members-at-Large Reina Bendayan, University of Toronto; Allen C. Templeton, Merck & Co., Inc; Annette Bak, AstraZeneca; Bernd W. Meibohm, the University of Tennessee Health Science Center; and President Dale E. Wurster and Past President Christopher R. McCurdy.

Source: AAPS

 

 


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.